Please ensure Javascript is enabled for purposes of website accessibility

The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind

By Brian Orelli, PhD – Feb 18, 2014 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Myraid Genetics, Sarepta Therapeutics, Questcor Pharmaceuticals, Ziopharm Oncology, and MannKind top the list of the most shorted biotechs.

Looking at a company's short interest should be an integral part of an investor's due diligence. A high short interest isn't necessarily a reason shun a company, but understanding why investors are shorting the stock is important. The shorts may be wrong, but investors should be able to convince themselves of that before hitting the buy button.

In the following slideshow, you'll find info on the five most shorted biotechs on the Nasdaq -- Myraid Genetics (MYGN 2.90%), Sarepta Therapeutics (SRPT 2.66%), Questcor Pharmaceuticals (NASDAQ: QCOR), Ziopharm Oncology (TCRT 6.80%), and MannKind (MNKD 3.43%) -- and a brief explanation on why each company is hated so much.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Sarepta Therapeutics Stock Quote
Sarepta Therapeutics
$126.25 (2.66%) $3.27
MannKind Corporation Stock Quote
MannKind Corporation
$4.82 (3.43%) $0.16
Alaunos Therapeutics, Inc. Stock Quote
Alaunos Therapeutics, Inc.
$0.68 (6.80%) $0.04
Myriad Genetics Stock Quote
Myriad Genetics
$20.93 (2.90%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.